克罗恩病:抗肿瘤坏死因子治疗初始剂量前后FDG PET/CT预测长期应答
这项前瞻性试点研究纳入8例活动性克罗恩病成人患者,在抗TNF治疗前及开始后2周行低剂量PET/CT,用SUVratio(SUVmax/肝脏SUVmean)评估FDG活性变化,并与盲法胃肠病学家临床应答评估、无激素缓解及CRP进行12个月随访比较。8例中7例2周时FDG活性下降,其中5例在8、26、52周达到临床应答和无激素缓解;1例FDG活性未下降者为临床无应答且未达无激素缓解。
要点
- 8例活动性克罗恩病患者在抗TNF初始剂量前及开始后2周行低剂量FDG PET/CT。
- 7例2周时FDG活性下降,其中5例在8、26、52周达到临床应答和无激素缓解。
- 1例FDG活性未下降者为临床无应答、CRP无下降且未达无激素缓解。
核心结论
- 在第二剂抗TNF诱导治疗前行FDG PET/CT所见的FDG活性变化,有潜力预测克罗恩病患者的临床应答和无激素缓解。
研究设计与样本
- 前瞻性、经机构审查委员会批准、符合《健康保险携带与责任法案》的试点研究,纳入8例活动性克罗恩病成人患者。
- 在抗TNF治疗前及开始后2周使用低剂量PET/CT评估FDG活性,测量最炎症肠段的SUVratio(SUVmax/肝脏SUVmean)。
- 将SUVratio变化与盲法胃肠病学家对临床应答和无激素缓解的评估以及CRP进行比较,随访12个月。
主要发现
- 8例患者中7例在2周时FDG活性下降,其中5例在8、26、52周达到临床应答和无激素缓解。
- FDG活性下降的其余2例在这些时间点未达到临床应答或无激素缓解,但CRP有下降。
- 1例FDG活性未下降者为临床无应答,CRP无下降,且未达到无激素缓解。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Clinical assessments of Crohn disease activity are limited in their capacity to assess treatment response to biologic therapy. The purpose of this study was to determine if changes in FDG activity between baseline PET and repeat PET performed prior to the second dose of induction anti-tumor necrosis factor (TNF) therapy correlate with clinical response. METHODS: In this prospective, institutional review board-approved, Health Insurance Portability and Accountability Act-compliant pilot study of 8 adult patients with active Crohn disease, FDG activity before and 2 weeks after initiation of anti-TNF therapy was assessed using low-dose PET/CT. FDG activity was measured in the most inflamed bowel loop using an SUVratio (SUVmax/liver SUVmean). Changes in SUVratio were compared with a blinded gastroenterologist assessment of clinical response and steroid-free remission, as well as C-reactive protein (CRP), during a 12-month follow-up period. RESULTS: Of 8 patients, 7 showed FDG activity decline at 2 weeks, 5 of whom achieved a clinical response and steroid-free remission at 8, 26, and 52 weeks. The remaining 2 patients with FDG activity decline did not achieve a clinical response or steroid-free remission at these time points, but there were reductions in CRP. The 1 patient without FDG activity decline was a clinical nonresponder, had no reduction in CRP, and did not achieve steroid-free remission. CONCLUSIONS: A change in FDG activity at FDG PET/CT performed prior to the second induction dose of anti-TNF therapy has the potential to predict clinical response and steroid-free remission in patients with Crohn disease.
引用
- Epelboym Y, Shyn PB, Chick JFB, et al. Crohn Disease: FDG PET/CT Before and After Initial Dose of Anti-Tumor Necrosis Factor Therapy to Predict Long-term Response. Clin Nucl Med. 2017. PMID: 28902728. doi:10.1097/RLU.0000000000001844
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。